FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4317567735> ?p ?o ?g. }

• W4317567735 endingPage "2085" @default.
• W4317567735 startingPage "2077" @default.
• W4317567735 abstract "The nephrotoxicity of bortezomib, a proteasome inhibitor, has not yet been elucidated, although tumor lysis syndrome (TLS) associated with multiple myeloma (MM) has been reported to increase after introduction of the drug. This study compared the incidence and risk factors for acute kidney injury (AKI) and TLS in patients with MM after bortezomib-based chemotherapy to investigate drug-related nephrotoxicity.From 2006 to 2017, 276 patients who underwent a first cycle of bortezomib-based chemotherapy for MM were identified in a single tertiary hospital. Laboratory TLS was defined according to the Cairo-Bishop definition. Development of AKI was assessed by AKI Network criteria within 7 days of the first chemotherapy.The median (interquartile range) age was 65 (56-72) years, and baseline estimated glomerular filtration rate (eGFR) was 61.3 (34.1-89.1) mL/min/1.73 m2. The incidences of AKI and laboratory TLS were 17% (n = 47) and 13% (n = 36), respectively. Ten (3.6%) subjects met both AKI and TLS criteria. Multivariate analyses showed that lower eGFR category [30-59, odds ratio (OR) 3.005 (95% confidence interval 1.163-7.976); 15-29, OR 4.225 (1.183-15.000); <15, OR 16.154 (3.831-70.920) vs ≥60, P < .001], lower serum albumin level [per 1 increase, OR 0.479 (0.256-0.871), P = .018], renal amyloidosis [OR 13.039 (4.108-44.041), P < .001] and use of acyclovir during bortezomib treatment [OR 3.689 (1.133-14.469), P = .042] were predictors of AKI. MM stages and β-2-microglobulin were not associated with increased risk of AKI. Regarding laboratory TLS, MM stage and β-2-microglobulin were higher in those with TLS than in others. In multivariate analyses, β-2-microglobulin level [OR 1.204 (1.005-1.461), P = .038] and absence of high-risk chromosome abnormalities [OR 0.143 (0.022-0.588), P = .016] were associated with higher risk of TLS.Development of AKI was often observed in the absence of TLS in patients with MM after treatment with bortezomib. In addition, the risk factors for AKI and TLS varied widely. These findings indicate the potential nephrotoxicity of bortezomib irrespective of TLS in patients with decreased kidney function." @default.
• W4317567735 created "2023-01-21" @default.
• W4317567735 creator A5000179774 @default.
• W4317567735 creator A5002966253 @default.
• W4317567735 creator A5022259689 @default.
• W4317567735 creator A5024213022 @default.
• W4317567735 creator A5043434058 @default.
• W4317567735 creator A5057672737 @default.
• W4317567735 creator A5079414878 @default.
• W4317567735 date "2023-01-20" @default.
• W4317567735 modified "2023-10-18" @default.
• W4317567735 title "Acute kidney injury in bortezomib-treated patients with multiple myeloma" @default.
• W4317567735 cites W1516702206 @default.
• W4317567735 cites W1917077964 @default.
• W4317567735 cites W1967251991 @default.
• W4317567735 cites W1967300023 @default.
• W4317567735 cites W2025434152 @default.
• W4317567735 cites W2045865836 @default.
• W4317567735 cites W2079622451 @default.
• W4317567735 cites W2080515779 @default.
• W4317567735 cites W2095514791 @default.
• W4317567735 cites W2118884380 @default.
• W4317567735 cites W2120087999 @default.
• W4317567735 cites W2134138207 @default.
• W4317567735 cites W2141169323 @default.
• W4317567735 cites W2155965977 @default.
• W4317567735 cites W2161648900 @default.
• W4317567735 cites W2166147915 @default.
• W4317567735 cites W2239147471 @default.
• W4317567735 cites W2319804562 @default.
• W4317567735 cites W2464059618 @default.
• W4317567735 cites W2510616238 @default.
• W4317567735 cites W2523191766 @default.
• W4317567735 cites W2610785983 @default.
• W4317567735 cites W3013063217 @default.
• W4317567735 doi "https://doi.org/10.1093/ndt/gfad016" @default.
• W4317567735 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36662030" @default.
• W4317567735 hasPublicationYear "2023" @default.
• W4317567735 type Work @default.
• W4317567735 citedByCount "0" @default.
• W4317567735 crossrefType "journal-article" @default.
• W4317567735 hasAuthorship W4317567735A5000179774 @default.
• W4317567735 hasAuthorship W4317567735A5002966253 @default.
• W4317567735 hasAuthorship W4317567735A5022259689 @default.
• W4317567735 hasAuthorship W4317567735A5024213022 @default.
• W4317567735 hasAuthorship W4317567735A5043434058 @default.
• W4317567735 hasAuthorship W4317567735A5057672737 @default.
• W4317567735 hasAuthorship W4317567735A5079414878 @default.
• W4317567735 hasConcept C119060515 @default.
• W4317567735 hasConcept C126189478 @default.
• W4317567735 hasConcept C126322002 @default.
• W4317567735 hasConcept C126894567 @default.
• W4317567735 hasConcept C156957248 @default.
• W4317567735 hasConcept C159641895 @default.
• W4317567735 hasConcept C2776364478 @default.
• W4317567735 hasConcept C2776694085 @default.
• W4317567735 hasConcept C2777478702 @default.
• W4317567735 hasConcept C2780091579 @default.
• W4317567735 hasConcept C2780306776 @default.
• W4317567735 hasConcept C2780472472 @default.
• W4317567735 hasConcept C71924100 @default.
• W4317567735 hasConcept C90924648 @default.
• W4317567735 hasConceptScore W4317567735C119060515 @default.
• W4317567735 hasConceptScore W4317567735C126189478 @default.
• W4317567735 hasConceptScore W4317567735C126322002 @default.
• W4317567735 hasConceptScore W4317567735C126894567 @default.
• W4317567735 hasConceptScore W4317567735C156957248 @default.
• W4317567735 hasConceptScore W4317567735C159641895 @default.
• W4317567735 hasConceptScore W4317567735C2776364478 @default.
• W4317567735 hasConceptScore W4317567735C2776694085 @default.
• W4317567735 hasConceptScore W4317567735C2777478702 @default.
• W4317567735 hasConceptScore W4317567735C2780091579 @default.
• W4317567735 hasConceptScore W4317567735C2780306776 @default.
• W4317567735 hasConceptScore W4317567735C2780472472 @default.
• W4317567735 hasConceptScore W4317567735C71924100 @default.
• W4317567735 hasConceptScore W4317567735C90924648 @default.
• W4317567735 hasIssue "9" @default.
• W4317567735 hasLocation W43175677351 @default.
• W4317567735 hasLocation W43175677352 @default.
• W4317567735 hasOpenAccess W4317567735 @default.
• W4317567735 hasPrimaryLocation W43175677351 @default.
• W4317567735 hasRelatedWork W2022616407 @default.
• W4317567735 hasRelatedWork W2037115108 @default.
• W4317567735 hasRelatedWork W2063107464 @default.
• W4317567735 hasRelatedWork W2093874596 @default.
• W4317567735 hasRelatedWork W2127896754 @default.
• W4317567735 hasRelatedWork W2155080636 @default.
• W4317567735 hasRelatedWork W2566477261 @default.
• W4317567735 hasRelatedWork W2613546412 @default.
• W4317567735 hasRelatedWork W2903842133 @default.
• W4317567735 hasRelatedWork W85206306 @default.
• W4317567735 hasVolume "38" @default.
• W4317567735 isParatext "false" @default.
• W4317567735 isRetracted "false" @default.
• W4317567735 workType "article" @default.